S ince early in the HIV epidemic in the United States, researchers have sought to provide decision makers with the best available information about the costs of HIV care and costs avoided by HIV prevention to support fiscal planning, program evaluation, resource allocation, and public health policy. [1] [2] [3] [4] [5] [6] We previously examined the lifetime cost of providing guideline-concordant care to HIV-infected adults in the United States in 2004. We estimated that the discounted lifetime cost from time of infection was $303,100 ($361,400 in 2012 USD). 7 This finding has been widely used as a benchmark for evaluating HIV prevention interventions. 8, 9 Recently, the Centers for Disease Control and Prevention (CDC) recommended prescribing preexposure prophylaxis in high-risk populations, a potentially highly effective but costly prevention intervention. 10 Updated cost and cost savings estimates are needed that reflect the reality of current HIV care in the United States, 11 including current treatments and treatment initiation practices, 12 costs for disease management of chronic HIV disease and other chronic diseases, 13 and inconsistent access and adherence to effective treatment. 14 Our objective was to project the lifetime medical cost avoided by averting 1 HIV infection in the United States, taking into account the medical costs that would have been incurred in the absence of HIV infection, considering costs of medications for conditions other than HIV, and incorporating realistic assumptions about lack of continuity of HIV care compared with optimal care delivery.
METHODS

Analytic Overview
We estimated the lifetime medical cost savings from averting 1 HIV infection. The analysis was conducted from the US health care system perspective. 15 We first estimated mean lifetime medical costs accrued by HIV-infected persons beginning at the time of HIV infection. We then subtracted the mean estimated lifetime costs accrued by demographically similar individuals who remain HIV uninfected. The estimation period began at age 35, which we estimated to be the mean age at infection in the United States. 15 We also conducted analyses in which the estimation period began at age 25 and 55.
For HIV-infected persons, we projected mortality and immune function (CD4 count distribution) using the Cost-Effectiveness of Preventing AIDS Complications (CEPAC) model, a widely published state-transition model of HIV disease. 7, 16, 17 Annual medical costs were estimated using data from the HIV Research Network (HIVRN). 18 These costs were stratified based on age, sex, race/ethnicity, HIV transmission risk factors [men who have sex with men (MSM), injection drug user (IDU), heterosexual sex], and CD4 count.
We estimated non-HIV mortality from race/ethnicity and sex-specific life tables from CDC. 19 We adjusted these estimates to reflect differences in mortality observed among HIV-uninfected MSM, IDU, and heterosexual individuals at risk of becoming HIV infected 20 (see Appendix, Supplemental Digital Content 1, http://links.lww.com/MLR/A860). We used age, race/ethnicity, and sex-specific costs from the 2009 Medical Expenditure Panel Survey (MEPS) to estimate annual medical costs of HIV-uninfected individuals. 21 We also considered the case where HIV infection is delayed-but not permanently averted-for 5 years. In this case we compared the discounted lifetime cost for individuals who become HIV-infected at age 35 to the discounted lifetime cost for individuals who are HIV-uninfected at age 35 and then become infected at age 40.
We addressed uncertainty about the medical costs by deriving cost distributions from 1000 random draws based on the SEs around the predicted costs provided by a generalized linear model for HIV-infected individuals and by using the MEPS SEs for HIV-uninfected individuals. The resulting empiric SEs (SDs of the distribution of mean values) are presented in parentheses after mean estimates.
Results are reported as projected lifetime medical costs in 2012 USD. Life expectancy results are reported undis-counted, and cost results are reported both undiscounted and discounted to present value at a 3% annual rate. 22 Discounted costs are highlighted throughout because they represent economic costs that take into account time preferences of individuals and society and the opportunity cost of funds. 22 
Computer Simulation Model
We used the CEPAC model of HIV natural history and treatment to project annual mortality and immune function status (represented by CD4 count 17 ) over time in a hypothetical cohort of newly HIV-infected individuals. In our analysis, patients enter the model at the time of HIV infection and follow natural disease progression until antiretroviral therapy (ART) initiation. Patients' HIV RNA level and current CD4 count determine their CD4 count decline. Patients in the model may die due to acute opportunistic infections, chronic HIV-related causes, or non-HIV-related causes. Risks for opportunistic infections and mortality depend on CD4 count. Non-HIV-related mortality is dependent on age, sex, race/ethnicity, and HIV transmission risk factor (MSM, IDU, heterosexual sex). 23 ART is initiated after simulated HIV-infected individuals enter HIV care, 12 and prophylaxis against opportunistic infections is initiated using the CD4 threshold criteria specified in US guidelines. 24 Once patients initiate ART, they have a probability of achieving virologic suppression and consequent CD4 count gain, with the greatest CD4 count gain during the first 2 months on therapy. 25 Increasing CD4 counts reduces the likelihood of developing opportunistic infections and HIV-related mortality. After achieving viral suppression, patients are subject to a monthly probability of virologic failure and a monthly probability of loss to follow-up while on ART. Probabilities of achieving virologic suppression, virologic failure, and loss to follow-up vary depending on ART adherence (see Appendix, Supplemental Digital Content 1, http://links.lww.com/MLR/A860).
Medical Services Utilization and Annual Cost Estimation
We used data from the HIVRN, a consortium of hospital-based and community-based HIV care sites in the United States, to calculate medical costs of HIV-infected individuals. 18, 26, 27 HIVRN sites annually abstract specified data elements from patients' medical records and assemble them into a uniform database. Of the 12 HIVRN sites that treat adult patients, 7 collect comprehensive prescription medication data. Analyses were limited to adult patients (18 y and above) at these 7 sites who were in HIV primary care, defined by having at least 1 visit to the primary HIV care provider and a CD4 count drawn between January 1, 2009 and December 31, 2009.
Each site provided data on several cost components: inpatient hospital days for any reason, outpatient primary care visits to the HIV clinic, emergency department visits for any reason, CD4 and viral load laboratory tests, and HIVrelated and HIV-unrelated prescription medications recorded in the HIV clinic charts. We counted the total numbers of outpatient visits to the HIV primary care provider, inpatient days, emergency department visits, CD4 tests, and HIV RNA tests for each patient within strata defined by median CD4 in 2009 (r50, 51-200, 201-350, 351-500, >500/mL). For each type of service, we estimated costs by multiplying utilization data by an appropriate unit cost estimate (see Appendix, Supplemental Digital Content 1, http://links.lww.com/MLR/ A860). Medical record data provided detailed information and start and stop dates on all prescribed medications. For each patient, we calculated the number of months that each medication was prescribed, which we multiplied by an estimated monthly cost based on the discounted Red Book average wholesale price for that medication. 27, 28 Total annual expenditures were the sum of estimated costs for each cost component.
To take into account variations in medical costs by patient demographics and immune status, we estimated a multivariable Poisson regression model that included sex, race/ ethnicity, HIV-risk group, age, CD4 count stratum, any ART use, and indicators for HIVRN provider site. For each combination of independent variables, we calculated mean predicted costs based on this model, averaging predictions across sites. The predicted annual costs were adjusted to 2012 USD using the medical care component of the Consumer Price Index 29 (Table 1 ) and served as inputs for the subsequent analysis.
To calculate annual medical costs of HIV-uninfected individuals, we used data from the MEPS, a nationally representative survey of households in the United States. 21 Using the online MEPS query tool, 21 we calculated the mean annual medical care expenditures from the MEPS household survey in 2009 stratified by sex, race/ethnicity, and age. We did not include costs of physical therapy, occupational therapy, chiropractic care, optometry, and home health care, because these costs were not included in the HIVRN cost estimates for HIV-infected individuals. We then adjusted these costs to 2012 USD (Table 1 ).
Base Case Analysis
We conducted analyses separately for 15 subpopulations: 5 transmission risk groups (MSM, male IDU, male heterosexual, female IDU, female heterosexual) stratified by race/ethnicity (white, black, Hispanic). CD4 at entry into care was specified separately for each population. 35, 36 We assumed ART was initiated for all individuals at care entry and retention was consistent with HIVRN sites' experience. Overall costs were estimated by an average of model results for the 15 subpopulations, weighted in proportion to each subpopulation's contribution to HIV incidence in the United States between 2006 and 2009. 15 This approach necessitated using only 1 age at time of infection for each analysis. For HIV-infected individuals, we used the CEPAC model to project the proportion of individuals alive in each year after HIV infection, stratified by CD4 category and whether the individuals were or were not in care and were or were not on ART. Probabilities of achieving virologic suppression, subsequent virologic failure, and loss to follow-up depend on model inputs for ART adherence (Table 1) . We then applied the relevant estimated annual costs from the HIVRN. We assigned to individuals out of care (pre-ART or lost to follow-up) the cost of care for HIV-infected individuals not on ART with the same demographic characteristics and CD4 count.
For HIV-uninfected individuals, we used the adjusted life tables to project annual mortality, 19, 20 assuming they remained HIV uninfected. Costs for each year were then applied using the relevant MEPS annual cost estimates for individuals remaining alive. Discounted annual costs were summed across years from age 35 until death. We were limited to choosing 1 initial age for each analysis by the overall method used to estimate costs, which requires a weighted average of model results for 15 subpopulations.
Sensitivity Analyses
We conducted a sensitivity analysis that assumed an optimal care scenario in which all HIV-infected individuals were identified and linked to care at a CD4 count of 500/mL, initiated ART immediately, and were never lost from care. We also varied costs to reflect the possibility that the HIVuninfected individuals would be more frequent users of medical services in this optimal care scenario even if they remained HIV uninfected. To consider the potential impact of the availability of generic antiretroviral medication regimens in the future, we conducted a sensitivity analysis in which we assumed the costs for 85% of individuals on firstline regimens would be reduced by 40%. 39 We also varied costs for HIV-infected individuals based on the 95% confidence interval around predicted costs for each subpopulation.
Additional sensitivity analyses included: varying the CEPAC model inputs for ART adherence (eg, proportion achieving Z95% adherence); assuming non-HIV mortality is that of individuals of the same sex, age, and race/ethnicity in the US population without further risk adjustment; and repeating the base case analyses assuming ages at infection of 25 and 55.
To incorporate the effect of secondary HIV transmission, we applied per person probabilities of sexual transmission during acute infection, postacute unaware, and postacute aware periods 40, 41 to HIV-infected patients alive in each year since infection. For each subpopulation, we assumed that each secondary transmission averted would accrue the same discounted incremental cost as the primary transmission starting at the time of secondary infection. The savings were discounted to present value and the sum of these additional cost savings was added to the base case cost savings. We assumed that if a secondary transmission did not occur in a given year, the HIV infection would not be permanently avoided due to ongoing risk behavior in the population, but would be delayed for 5 years before the infection eventually occurred.
RESULTS
Base Case
On the basis of the current data on time of entry into HIV care, 36 estimated life expectancy for persons who became HIV infected in 2012 at age 35 15 is 29.5 years and discounted mean lifetime medical cost is $326,500 (SE, $2100). Of the total cost, 60% is for antiretroviral medications, 15% is for chronic disease medications and for opportunistic infection prophylaxis and treatment medications, and 25% is for nonmedication costs (Fig. 1 ). Undiscounted mean lifetime costs are $597,300 ($4200). After entry into care, which was estimated using the CEPAC model to occur on average 5.1 years after infection, individuals spend 17% of total life years with CD4 < 500/mL and 83% with CD4Z500/mL. For individuals who remain uninfected, estimated life expectancy is 38.1 years, discounted lifetime cost is $96,700 ($2700), and undiscounted lifetime cost is $197,100 ($5400). Therefore, the estimated discounted medical cost saved by avoiding an HIV infection, based on current linkage to and retention in HIV care, is $229,800 ($3400) ($326,500 À $96,700, Table 2 ).
Across the 15 subpopulations, life expectancies vary from 13.9 to 34.2 years for HIV-infected and from 15. 
Results of Sensitivity Analyses
For individuals who receive optimal care, estimated life expectancy is 33.5 years, discounted lifetime cost is $435,200 ($2700), antiretroviral medications costs are 47% higher than the base case, and other medication and nonmedication costs are 13% higher than the base case ( Fig. 1) . Estimated undiscounted lifetime cost is $798,300 ($5800). The discounted medical cost saved by avoiding an HIV infection, assuming this optimal HIV care, is estimated at $338,400 ($3600). If costs for HIV-uninfected individuals are also increased by 13%, the discounted medical cost saving for the optimal care scenario is estimated at $326,100 ($3600).
Additional sensitivity analyses indicate that the discounted cost saving is $188,400 ($3300), 13% lower than the base case, when assuming first-line antiretroviral treatment with generic medication regimens. Results are also sensitive to model assumptions about ART adherence and medical costs at the highest and lowest estimates for HIV-infected individuals ( Table 2 ). Assuming HIV-infected individuals out of care incurred only hospitalization costs yielded results similar to using the lowest medical cost estimates (results not shown). Discounted cost savings increase by 7% to $245,600 ($3300) when non-HIV mortality is based on life tables without adjustment by risk group.
Discounted savings vary substantially depending on whether primary HIV infections are temporarily delayed rather than permanently avoided as assumed in the base case.
For example, discounted lifetime medical cost savings are $49,500 ($2900) if a primary infection is delayed for 5 years (Fig. 2 -difference between solid and dotted lines) versus $229,800 ($3400) if the infection is avoided (Fig. 2 -difference between solid and dashed lines). Discounted savings also vary depending on age at HIV infection, ranging from $248,700 ($3000) discounted lifetime medical savings if an infection is permanently avoided in a 25-year-old individual to $146,300 ($4100) if an infection is permanently avoided in a 55-year-old individual. The impact of assuming the HIV infection is temporarily delayed rather than permanently avoided also varies by age of infection (Appendix Figs. 1, 2 , Supplemental Digital Content 1, http://links.lww.com/MLR/ A860).
Impact of Secondary Transmission
In sensitivity analyses that included secondary transmission, the average HIV-infected person is expected to transmit HIV to 0.97 HIV-uninfected persons over his or her lifetime. The discounted medical cost saved by avoiding an HIV infection and delaying secondary transmission by 5 years is $270,300 ($229,800+$40,500).
DISCUSSION
Effective treatment has increased life expectancy after HIV infection, and deaths from non-AIDS-related causes now exceed deaths from AIDS for those with HIV in the United States. 42 Medical costs of treating HIV-infected individuals as they age now include costs of both HIV-related and HIV-unrelated medical care. We estimated the medical cost saved by averting 1 HIV infection in the United States, taking into account the costs that would have been incurred 
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Medical Care Volume 53, Number 4, April 2015 by similar at-risk individuals in the absence of HIV infection. We project discounted medical cost savings of $229,800 by permanently averting 1 HIV infection based on current care patterns in the United States and $49,500 if 1 HIV infection is delayed by 5 years. Our analysis shows that as HIV care becomes more effective, the cost avoided by averting 1 HIV infection also increases. Improved care is cost-effective by accepted standards in the United States, it is not cost saving. 43 The added years of life, however, result in additional costs for treatment that would not have occurred in the absence of an infection. Our projections of lifetime medical costs for HIV-infected individuals of $326,500 in the base case and $435,200 in the optimal care case are comparable with recent model-based estimates of lifetime costs for individuals in the United States entering care with CD4 201-350/mL ($332,300 in 2012 USD) and >500/mL ($443,000), respectively, 44 and costs from entry into care (not shown) are consistent with previous estimates of these costs in France using the CEPAC model. 45 Our projection of medical cost savings of $229,800 is substantially lower than the previous estimate of $303,100 in 2004 USD ($361,400 in 2012 USD) 7 for several reasons. First, we now account for medical costs that would have been incurred in the absence of an HIV infection. Second, our previous analysis did not adjust mortality for risk group characteristics that lower average life expectancy, 23 thereby reducing costs, nor did they adjust costs for health service utilization by different risk groups. Our life expectancy estimates are lower than 2 other recent modelbased analyses in the United States and the United Kingdom, 44, 46 likely reflecting the race/ethnicity and risk-category mortality effects in our model. Our results are consistent with these models, however, in projecting substantial life expectancy losses associated both with becoming HIV infected and with delayed initiation of treatment after infection.
Consistent with other analyses, 7, 44 we found that ART medications represent the largest component of cost for HIVinfected individuals. We found that non-HIV chronic care medications represent a substantial component of cost as well, emphasizing the significant cost of managing non-HIV comorbidities in an aging HIV-infected population. 13, 47 These comorbidities are frequently managed by HIV primary care providers. 48 Our results are somewhat sensitive to assumptions about future use of generic HIV drugs in the United States. This points to the potential importance of future availability of generic drugs in lowering the cost of HIV care, depending on regimens selected and adherence. 39 Our analysis also indicates that the value of HIV primary prevention may be greater when the effects of preventing secondary transmission to HIV-uninfected partners are taken into account, which would increase the value of interventions targeting individuals at high risk of transmitting to multiple partners. The magnitude of this impact is greater the longer individuals remain uninfected after avoiding a secondary transmission. The current relatively stable HIV incidence trends in the United States 15 suggest these uninfected partners are at high risk for eventual HIV infection. If the probabilities of secondary transmission we used already take into account this additional risk, the value of primary prevention would be even higher.
Our analysis is subject to several limitations. By focusing on health system costs, our analysis does not reflect quality-of-life gains and broader societal benefits of avoiding HIV infections. The unit costs we applied to determine lifetime medical costs for HIV-infected individuals represent costs to the health care system. In contrast, the costs applied to non-HIV-infected individuals were from the MEPS survey that collected data on medical expenditures, which may be different from costs to the health care system. Although we removed out-of-pocket costs and costs reported in MEPS for services not included in HIVRN, which could lead to a slight underestimate of costs for HIV-infected individuals, costs for HIV-uninfected individuals may be overstated nevertheless. In contrast, costs for HIV-infected individuals may be overstated because, in the base case, we assume that their costs before diagnosis and when lost to follow-up are similar to those of HIV-infected individuals with the same CD4 count who are in care but not receiving ART.
Model-based analyses use available data to project future mortality and costs. To address this limitation, we conducted several sensitivity analyses to consider the impact of potential improvements in ART efficacy and reductions in the cost of ART, which are the principal drivers of life expectancy and total cost for HIV-infected individuals. We did not explicitly model the impact of hepatitis C infection and treatment; treatment options for HCV are evolving rapidly, and future HCV treatment efficacy, costs, and acceptance in HIV coinfected populations are uncertain. 49 Our lifetime cost projections include HIV-related medical costs and some HIVunrelated medical costs, but we also did not separately model end-of-life care costs or other specific comorbidities when deriving these estimates 50 ; explicitly modeling comorbidities could result in shorter forecasted life expectancies but higher costs while alive. Our health services utilization data from HIVRN include data from individuals across a broad range of demographics, ensuring representation of costs associated with comorbidities and aging. Nevertheless data collected in 2009 may not reflect current services utilization. There were some medical services that HIVRN did not capture because patients received services from providers outside the HIVRN or from HIVRN providers who were not designated as the primary HIV provider. The HIVRN data also did not include diagnostic tests and procedures other than CD4 and HIV RNA tests. The estimated savings associated with prevention of HIV disease would be higher if these costs were included.
The costs to society of an HIV infection extend well beyond the medical domain, including social services, housing, patient time, lost productivity, and physical and emotional distress to patients and their families. Estimates of medical costs averted represent a lower bound on the societal value of averting HIV infections. Nevertheless, the potential medical cost savings from avoiding or even delaying HIV infections in the United States are substantial, given the high cost of HIV treatment. Combination prevention interventions, including targeted preexposure prophylaxis, that fundamentally address transmission and reduce HIV incidence have the potential to permanently prevent HIV infections. 51 With greater success in effectively treating HIV as a chronic disease, the economic value of HIV prevention in the United States increases.
